Replimune Group, Inc. entered into an underwriting agreement to issue and sell 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 additional shares at a combined offering price of approximately $12.06 per share. The transaction is expected to generate net proceeds of roughly $140.5 million after deducting underwriting discounts and estimated expenses. Closing is anticipated on or about August 11, 2026. This amendment corrects the beneficial ownership limitations for the pre-funded warrants previously disclosed in an earlier filing.
